Show simple item record

dc.contributor.authorChen, Shuxiong
dc.contributor.authorEvert, Benjamin
dc.contributor.authorAdeniyi, Adetayo
dc.contributor.authorSalla-Martret, Mercè
dc.contributor.authorLua, Linda H-L
dc.contributor.authorOzberk, Victoria
dc.contributor.authorPandey, Manisha
dc.contributor.authorGood, Michael F
dc.contributor.authorSuhrbier, Andreas
dc.contributor.authorHalfmann, Peter
dc.contributor.authorKawaoka, Yoshihiro
dc.contributor.authorRehm, Bernd HA
dc.date.accessioned2021-11-09T01:43:20Z
dc.date.available2021-11-09T01:43:20Z
dc.date.issued2021
dc.identifier.issn2192-2640
dc.identifier.doi10.1002/adhm.202102089
dc.identifier.urihttp://hdl.handle.net/10072/409975
dc.description.abstractThere is an unmet need for safe and effective SARS-CoV-2 vaccines that are stable and can be cost-effectively produced at large scale. Here, we used a biopolymer particle (BP) vaccine technology that can be quickly adapted to new and emerging variants of SARS-CoV-2. We describe coronavirus antigen-coated BPs as vaccines against SARS-CoV-2. The spike protein subunit S1 or epitopes from S and M proteins (SM) plus/minus the nucleocapsid protein (N) were selected as antigens to either coat BPs during assembly inside engineered Escherichia coli or BPs were engineered to specifically ligate glycosylated spike protein (S1-ICC) produced by using baculovirus expression in insect cell culture (ICC). BP vaccines were safe and immunogenic in mice. BP vaccines, SM-BP-N and S1-ICC-BP induced protective immunity in the hamster SARS-CoV-2 infection model as shown by reduction of virus titres up to viral clearance in lungs post infection. The BP platform offers the possibility for rapid design and cost-effective large-scale manufacture of ambient temperature stable and globally available vaccines to combat the COVID-19 pandemic. This article is protected by copyright. All rights reserved.
dc.languageeng
dc.publisherWiley
dc.relation.ispartofpagefrome2102089
dc.relation.ispartofjournalAdvanced Healthcare Materials
dc.subject.keywordsCOVID-19
dc.subject.keywordsSARS-CoV-2
dc.subject.keywordsbiopolyester
dc.subject.keywordsself-assembly
dc.subject.keywordsvaccine
dc.titleAmbient Temperature Stable, Scalable COVID-19 Polymer Particle Vaccines Induce Protective Immunity
dc.typeJournal article
dcterms.bibliographicCitationChen, S; Evert, B; Adeniyi, A; Salla-Martret, M; Lua, LH-L; Ozberk, V; Pandey, M; Good, MF; Suhrbier, A; Halfmann, P; Kawaoka, Y; Rehm, BHA, Ambient Temperature Stable, Scalable COVID-19 Polymer Particle Vaccines Induce Protective Immunity., Advanced Healthcare Materials, 2021, pp. e2102089
dc.date.updated2021-11-07T22:50:52Z
dc.description.versionAccepted Manuscript (AM)
gro.description.notepublicThis publication has been entered in Griffith Research Online as an advanced online version.
gro.rights.copyright© 2021 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. This is the peer reviewed version of the following article: Ambient Temperature Stable, Scalable COVID-19 Polymer Particle Vaccines Induce Protective Immunity, Advanced Healthcare Materials, 2021, which has been published in final form at https://doi.org/10.1002/adhm.202102089. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving (http://olabout.wiley.com/WileyCDA/Section/id-828039.html)
gro.hasfulltextFull Text
gro.griffith.authorRehm, Bernd
gro.griffith.authorGood, Michael F.
gro.griffith.authorChen, Shuxiong
gro.griffith.authorEvert, Ben J.
gro.griffith.authorPandey, Manisha
gro.griffith.authorOzberk, Victoria


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record